Portal de Periódicos da CAPES

Favorable prognostic impact of RAS mutation status in multiple myeloma treated with high-dose melphalan and autologous stem cell support in the era of novel agents: a single center perspective

2015; Taylor & Francis; Volume: 57; Issue: 1 Linguagem: Inglês

10.3109/10428194.2015.1046863

1042-8194

Niklas Gebauer, Harald Biersack, Ann-Cathrin Czerwinska, Janina Schemme, Tim Tristan Hardel, Veronica Bernard, Dirk Rades, Hendrik Lehnert, Kim Luley, Christoph Thorns,

Peptidase Inhibition and Analysis

Oncogenic mutations affecting members of the RAS gene family (NRAS, KRAS, HRAS) have been recurrently described in many solid tumors and hematological malignancies including multiple myeloma in a v...